Zydus Lifesciences Ltd
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
Strengths
- +Company has delivered good profit growth of 31.4% CAGR over last 5 years
- +Company has been maintaining a healthy dividend payout of 22.6%
- +Company's working capital requirements have reduced from 135 days to 74.4 days
Weaknesses
- −Company has high debtors of 197 days.
Shareholding Pattern
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 74.98% | 74.98% | 74.98% | 75%▲0.0 | 75% | 75% | 75% | 75% |
| FIIs | 5.59% | 7.52%▲1.9 | 7.53%▲0.0 | 7.31%▼0.2 | 7.13%▼0.2 | 7.34%▲0.2 | 7.06%▼0.3 | 6.95%▼0.1 |
| DIIs | 12.56% | 10.59%▼2.0 | 10.61%▲0.0 | 10.95%▲0.3 | 11.09%▲0.1 | 10.86%▼0.2 | 11.08%▲0.2 | 11.2%▲0.1 |
| Public | 6.81% | 6.85%▲0.0 | 6.85% | 6.69%▼0.2 | 6.74%▲0.0 | 6.81%▲0.1 | 6.86%▲0.1 | 6.86% |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,159 | 2,371 | 3,332 | 4,160 | 2,621 | 2,516 | 5,820 | 2,588 | 2,871 | 2,284 |
| Expenses | 1,510 | 1,672 | 1,763 | 1,787 | 1,678 | 1,867 | 2,047 | 2,003 | 1,719 | 2,085 |
| Operating Profit | 649 | 699 | 1,569 | 2,373 | 942 | 648 | 3,773 | 585 | 1,152 | 199 |
| OPM % | 30% | 29% | 47% | 57% | 36% | 26% | 65% | 23% | 40% | 9% |
| Net Profit | 805 | 450 | 1,405 | 1,701 | 790 | 471 | 2,814 | 385 | 1,157 | 296 |
| EPS ₹ | 7.95 | 4.45 | 13.96 | 16.9 | 7.85 | 4.68 | 27.96 | 3.82 | 11.49 | 2.95 |
AI Insights
TTM revenue at ₹13,563Cr, down 10.3% YoY. OPM at 42%.
Borrowings at ₹7,682Cr. Debt-to-equity ratio: 0.36x. Healthy balance sheet.
CWIP at ₹1,004Cr (22% of fixed assets). Significant capex underway — growth runway building.
DIIs: 11.2% (-2.24pp change). FIIs: 6.95% (+2.91pp change). Promoters hold 75%.
ROCE improving from 20% (Mar 2014) to 31% (Mar 2025). Working capital days: 74.
PE 21.2x with 30.6% ROCE. Price is 361% above book value of ₹215. Dividend yield: 1.11%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Acquisition 13 May - Zydus will acquire Assertio for USD 23.50 per share in cash, totaling about USD 166.4 million.
- Receipt Of Demand Order-In-Appeal From Appellate Authority, Central Goods And Services Tax Appeals Commissionerate, Chandigarh 13 May - GST appellate authority upheld Rs. 1.71 million demand and Rs. 10.12 million penalty; company to file second appeal.
- Update on board meeting 13 May - Board meeting on May 19, 2026 will consider buyback of fully paid-up equity shares.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 13 May - Q4 FY26 post results earning call details
- Announcement under Regulation 30 (LODR)-Cessation 13 May - Mr. Apurva S. Diwanji ceased as Independent Director effective May 12, 2026, after completing tenure.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse